No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HQY240621P55000
- 2.60
- 0.000.00%
15min DelayTrading Nov 16 15:06 ET
0.00High0.00Low
0.00Open2.60Pre Close0 Volume0 Open Interest55.00Strike Price0.00Turnover690.84%IV36.60%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry2.60Extrinsic Value100Contract SizeAmericanOptions Type-0.1223Delta0.0057Gamma31.79Leverage Ratio-2.3711Theta-0.0005Rho-3.89Eff Leverage0.0104Vega
Intraday
- 5D
- Daily
News
Demystifying HealthEquity: Insights From 11 Analyst Reviews
HealthEquity (NASDAQ:HQY) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The following table provides a quick overview of
HealthEquity Is Maintained at Overweight by Wells Fargo
HealthEquity Is Maintained at Overweight by Wells Fargo
Wells Fargo Maintains HealthEquity(HQY.US) With Buy Rating, Raises Target Price to $110
Wells Fargo analyst Stan Berenshteyn maintains $HealthEquity(HQY.US)$ with a buy rating, and adjusts the target price from $107 to $110.According to TipRanks data, the analyst has a success rate of 59
Express News | HealthEquity, Inc. : Wells Fargo Raises Target Price to $110 From $107
Why HealthEquity (HQY) Is a Top Growth Stock for the Long-Term
Wasatch Small Cap Growth Strategy's Investment in HealthEquity (HQY) Paid Off in Q1
Comments
HealthEquity's high P/S ratio could possibly be due to market expectations for future growth. The current justification for the high ratio lies on the low chance of decreased revenues, which investors expect to uphold share price.
Despite expenses reducing earnings last year, HealthEquity's future outlook remains positive. Unusual items don't typically recur, suggesting underestimated earning potential. The firm returned to profitability this year.
Despite HealthEquity's revenue growth and share price rise over three years, short-term underperformance and negative five-year returns are concerning. Fundamental improvements are required for shareholder confidence. Analyst forecasts could shed light on the company's future.
Read more